ably occurred with height and weight growth, requires an increase in the body's protein content. The body's protein content in turn will increase if the net protein synthesis (S-B) is positive. Since protein synthesis is an energy expensive process (8), while protein breakdown is not, the enhancement of net protein synthesis by a reduction of protein breakdown relative to protein synthesis is clearly an energy efficient adaptation permitting increased growth at a minimal energy expenditure. 7 fetuses, control or treated (regardless of the type of hormonal treatment). Thus T4 and glucocorticoids produce different effects on developing fetal brain and heart insulin receptors, along with a depletion of the myocardial glycogen stores. (Pediatr Res 19: 192-198,1985) Abbreviations T4, thyroxine T3, triiodothyronine
Glucose is an essential fuel for the metabolism of vital organs such as the brain and the heart (5, 36) . Insulin promotes glucose uptake in various adult (9, 6, 28) and fetal tissues (30) . Since the biologic effects of insulin are mediated by binding to specific tissue receptors, a change in the physical characteristics of these receptors as well as changes in postreceptor events may influence fetal anabolic processes (24) . Hormones that antagonize the effects of insulin modulate insulin receptor characteristics in both the adult (2, 12, 16, 25) and fetus (1 1,34) . Insulin influences the growth and metabolism of fetal organs (18, 30) . T4 and glucocorticoids may modify this effect of insulin, since both these hormones have been demonstrated to alter the insulin receptors (10, 11, 34) .
In the human fetus, glucocorticoids are administered to stimulate surfactant synthesis (19) and the use of thyroid hormones is contemplated in situations where the effect of glucocorticoids is limited (14, 21) . It is therefore important to define the effects of these hormones on other organs in the fetus. In this study, we investigated the influence of T4 and glucocorticoids on the maturation of the insulin receptor along with certain metabolic events in two vital organs, the fetal brain and heart.
MATERIALS AND METHODS
Animals. Pregnant New Zealand White rabbits of known gestation (term -3 1 days) were assigned to one of the five groups: 1) T4 treatment (30 days gestation-n = 7; 27 days-n = 3); 2) control I (n = 6); 3) steroid treatment (n = 6); 4) control I1 (n = 6); and 5) T4 and steroid treatment (n = 4).
The T4 treatment group of animals (n = 7) received intramuscular injections of T4 at 50 pglkg body weight every other day for a total of five injections from day 2 1 to 29 of gestation. This dose is approximately three times the dose reported to maintain a maternal euthyroid state in does rendered hypothyroid with propylthiouracil(l1).
Another small group of pregnant rabbits (n = 3) received a total of five doses of T4 (50 pg/kg every other day) between days 18 and 26 of gestation. This group was included to compare the effects of T4 on 27-and 30-day-old fetuses. Animals in this small subgroup were sacrificed at 27 day of gestation. Control I animals received 0.1 ml of normal saline on alternate days between days 2 1 and 29 of gestation.
The steroid-treated animals received betamethasone (0.085 mg/kg) on days 25 and 26 of gestation. This dose has been shown to suppress endogenous maternal and fetal corticosteroid production and modulate fetal lung and liver insulin receptors without altering fetal plasma insulin concentrations (1 1, 34) . Control I1 animals received two 0.1 ml intramuscular injections of normal saline on days 25 and 26 of gestation.
The T4 plus steroid treatment group of pregnant does (n = 4) received 50 pglkg of T4 every other day (a total of five doses) from day 18 to 26 of gestation. In addition on days 25 and 26 of gestation these animals received 0.085 mglkgldose of betamethasone.
The T4 treated and control I animals were sacrificed on day 30 of gestation. The steroid treated, control I1 and T4 + steroid treated animals were sacrificed on day 27.
Immediately prior to sacrifice, maternal arterial blood was collected. Animals were sacrificed by intravenous pentobarbitone; fetal (free flowing) blood was collected after decapitation for measurements of plasma glucose, free T4, total T3, and insulin concentrations (1 1). Fetal blood collected in this manner yields results comparable to values reported previously by us (1 1, 34) and other investigators (23) .
Plasma membranes. Brain plasma membranes were prepared by the method of Havrankova and Roth (I 5) and cardiac plasma membranes by the method of Rockson et al. (27) . Briefly fetal brains from a litter were removed from the cranium and pooled prior to homogenization in a Dounce glass homogenizer containing 1 mM bicarbonate buffer (pH 8.0). The homogenate was centrifuged at 600 x g for 1G min at 4" C. The pellet was discarded and the supernatant centrifuged at 20,000 x g for 30 min. The final pellet was resuspended in 1 volume of 50 mM Tris buffer for every gram of original brain weight.
Hearts from a litter (two litters when there was insufficient tissue) were pooled, trimmed, minced, and homogenized in 10 vol of 0.25 M Tris, 1 mM MgC12, 5 mM EGTA using a Dounce glass homogenizer. After filtering through two layers of cheesecloth, the homogenate was centrifuged at 3000 x g for 10 min. The pellet was resuspended in 0.75 ml of buffer per gram of original heart weight.
Protein concentration of both the brain and heart homogenates and membranes was estimated by the method of Lowry (20) . Organ DNA content was determined by Zamenof s modification (38) of Burton's technique (4). 5'-Nucleotidase activity in brain and heart homogenates, brain plasma membranes, and heart plasma membranes was measured as described before (1). The 5'-nucleotidase activity in all membranes studied was unchanged, regardless of T4 or steroid treatment. In comparison with the respective tissue homogenates, a 2-fold enrichment of the enzyme activity in the brain plasma membranes and a 1.6-fold enrichment in the heart dasma membrane was observed. Brain, heart, and liver glycogei was quantified by hydrolysis and estimation of glucose (26) .
Insulin binding assay. The ['251]insulin binding assay was performed as described previously (I I), with the exception of the final assay pH (8.0 for the brain and 7.4 for the heart) ( Fig. 1) . In addition -70,000 cpm of labeled insulin (specific activity -100 to 150 mCi/mg) for the brain and -35,000 cpm for the heart were used as the ligand. Membrane protein concentrations of 50 to 100 pg (heart) and 200 pg (brain) per tube were used. Scatchard plots of insulin binding data were used to determine total binding capacities (RO) and mean association constants (Ke) for receptors (29) . The curvilinear Scatchard plots were resolved into two components, a high affinity low capacity component (Rl) and low affinity high capacity component (R2). The association constants (K1 and K2) for these two components, respectively, also were calculated (35) . Binding capacities in mollliter were converted to number of receptors per microgram protein.
Other assays. Plasma glucose was measured by a glucose oxidase method (1 1). Plasma insulin (33) and serum-free T4 concentrations (33) were determined by specific radioimmunoassays as described previously. Serum total T3 concentrations were measured using a T3 immunophase RIA kit (Coming Medical, Medfield, MA). The sensitivity of the assay is 0.1 ng/ ml. Interassay and intraassay coefficient of variation was less than 4%. The antibody cross-reacts 100% with L-triiodothyronine, 72% with D-triiodothyronine, 27% with triiodothyroacetic acid, 0.14% with D-thyroxine, and 0.12% with L-thyronine.
Statistics. All data are presented as a mean k SEM. Statistically significant differences between the treated and the respective control groups was determined by the two-tailed Student's t test. Analysis of variance was employed when more than two groups were compared simultaneously. Correlation between the maternal and fetal plasma-free T4 concentrations in the T4-treated group of animals was determined by linear regression analysis. steroid-treated and control I1 groups; the mean weights were statistically similar in the three groups. As expected, the fetal body and organ weights were greater at 30 days than at 27 days of gestation. In addition, both the brain and heart DNA contents were similar in the T4-treated group and the T4 + steroid-treated group when compared to their rcspective controls. Heart DNA content decreased from 1.82 + 0.06 to 1.43 + 0.12 mg/g ( p < 0.02), in response to steroid treatment; there was no change in brain DNA content in response to steroid treatment. The protein content as described in other organs (37) increased from 51.58 + 1.98 to 56.63 f 0.68 mg/g ( p < 0.05) in the T4-treated fetal brain and from 89.17 + 4.08 to 105.9 f 3.5 mg/g ( p < 0.02) in the T4-treated fetal hearts. A similar increase was observed in both organs in response to T4 + steroid treatment. Steroid treatment alone, however, did not alter brain or heart protein content.
Plasma glucose and plasma/serum hormone concentrations are depicted in Table 2. T4 treatment increased Table 3 . Using brain plasma membranes, no difference in percent specific [1251]insulin binding (Fig. 2, Table 3 ), RO, R1, and R2 is observed between the T4-treated and control I fetuses. Conversely in the T4-treated heart plasma membranes, an increase from 3. 3.4 (4) 0.24 3.5 (5) 0. + 0.0002 ( p < 0.001) in the steroid-treated and T4 + steroidtreated fetuses, respectively, was observed. Total brain glycogen content in all five groups was less than the sensitivity of the assay and thus undetectable. The sensitivity of the glycogen assay is 0.025 pM glucosyl units/100 pl or 0.1 g of brain tissue. Glycogen content in both organs was measured as an end product of insulin-regulated glucose uptake by myocardial and brain cells. In addition, fetal liver glycogen content was quantified and noted to be no different in the T4-treated and control I groups (2 15 & 11.8 versus 210 f 8.8 pM glucosyl units/g wet weight).
DISCUSSION
Previously we demonstrated that administration of T4 at 25 pglkg every other day for a total of three doses (75 pglkg) to hypothyroid pregnant does rendered them euthyroid, without affecting the low fetal-free T4 levels ( I 1). However, in the present study, we observed that administration of a higher dose of T4 to euthyroid pregnant does (total of 250 pglkg) results in high maternal and fetal-free T4 levels. The high serum T4 levels exert a biologic effect in the fetus. In addition we demonstrated an increase in cardiac insulin receptors with a decrease in glycogen content in the T4-treated fetuses. Our results are consistent with Fig. 3 . Percent ['251]insulin binding to heart plasma membranes and myocardial glycogen content in pmol glucosyl unitslmg protein in control I and T4-treated 30-day gestation fetuses; and in control 11, steroidtreated, and T4 + steroid-treated 27-day gestation fetuses. p * < 0.05, ** < 0.02, when compared to their respective gestational age-matched control group. previous observations that T4 increased the insulin receptor number of adult adipocytes (16) and hypothyroidism was associated with a decrease in fetal lung and liver insulin receptors (I 1, 34) .
Following maternal administration of a synthetic thyroxine preparation, 3,5, dimethyl 3' isopropyl thyronine, which more readily crosses the placenta, a depletion in fetal myocardial glycogen has been observed (23) . In the present study, no effect of the T4 treatment on fetal liver glycogen content was observed. In a preliminary experiment (n = 6), at twice the dose of T4 administered in this study (i.e. 500 pglkg), we observed a depletion of fetal liver glycogen (7). These observations suggest that in the fetus, myocardial glycogen is more sensitive than liver glycogen to the effects of T4.
In the adult heart, insulin specifically promotes glycogen synthesis by increasing the glycogen synthase enzyme activity with little or no effect on phosphorylase activity (22) . However, the phosphorylase enzyme system is hypersensitive to insulin antag-onists, e.g. a and / 3 adrenergic agonists and glucagon (1 7). Plasma insulin concentrations remaining constant and an increase in insulin receptor number with unchanging postreceptor events should increase the biologic effect of insulin and augment glucose uptake. This has been demonstrated in the adult (24) . However, the fetus is relatively resistant to insulin; peripheral glucose uptake increases only when pharmacologic doses of insulin are administered (30) , and glucose challenge produces a relatively obtunded insulin response (32) . In addition, a delayed maturation of insulin-induced glucose uptake versus amino acid uptake has been demonstrated in fetal hepatocytes (3 1) .
Besides an increase in the myocardial insulin receptor number, the effect of T4 on various enzymes regulating glycogen synthesis is not clear. An activation of myocardial phosphorylase and an acceleration of glycogen depletion coincides with the postnatal period of physiologic T4 surge in the neonate (13) . T4 (3,5,dimethyl3' isopropyl thyronine) also evokes a depletion of myocardial glycogen in a hyperinsulinemic fetus of an alloxandiabetic mother (23) . This suggests that T4 alters the enzyme activity that controls glycogen metabolism. The influence of T4 on postreceptor events may be responsible for the depletion of myocardial glycogen. T4, by independently modulating the insulin receptor and postreceptor action(~), thus dissociates the physical characteristics of the receptor and the biologic function. In association with the decrease in cardiac glycogen stores, a slight increase in fetal plasma glucose concentration was noted in the present study. No similar change in maternal glucose values was observed possibly due to the dilutional effect in the large maternal pool. Again an increase in fetal plasma glucose values did not stimulate a rise in fetal insulin concentrations, due to an obtunded fetal pancreatic islet cell response to a glucose challenge (32) .
During the same developmental period, no modulation by T4 of fetal brain insulin binding or receptor number was observed. Most biochemical events of physiologic significance in the brain, such as the synthesis of myelin lipids, occur postnatally (8) . In the presence of a change in cardiac insulin receptor number, an absence of a change in brain insulin receptor characteristics signifies a difference in organ maturity or a different response by separate organs to the same stimulus.
Glucocorticoid treatment did not change fetal cardiac ['251] insulin binding despite elevated serum-free T4 concentrations. Although the free T4 levels after steroid treatment were similar to the levels achieved with T4 treatment alone, no increase in the insulin binding akin to that observed in response to T4 treatment alone was demonstrated. On the contrary, the steroidinduced decrease in ['251]insulin binding and receptor number observed in the fetal liver (34) was absent in the myocardium. The influence of high T4 concentrations was masked by the effect of the steroids in the fetus. In addition, a reduction in the heart glycogen content along with an increase in fetal glucose concentrations was noted in response to steroid treatment alone. Although during development changes in the fetal liver insulin receptor characteristics secondary to steroid treatment have been demonstrated (34) , the lack of change in brain [1251]insulin binding may again be due to organ maturational differences. T4 + steroid treatment also resulted in an absence of a change in either the fetal myocardial or the brain ['251]insulin binding. However, a marked depletion of myocardial glycogen with an elevation of plasma glucose levels was observed as an additive effect of T4 and steroids.
Our studies demonstrate that the fetal brain insulin feceptor is not modulated by the systemic hormonal changes that modulate the cardiac receptor. This suggests a relative unresponsiveness on the part of fetal neural tissue. On the other hand, in the fetal myocardium, combined T4 and steroid treatment neutralize the effect of either hormone alone on insulin binding (an increase in number by T4 and an absence of a decrease by steroids).
Although the physiologic significance remains unclear, we have demonstrated an additive interaction between T4 and betamethasone with regard to myocardial glycogen depletion. The sensitive period for a T4 effect on human fetal insulin receptors has not been defined; besides 10 days of T4 therapy in the rabbit fetus cannot be related to the clinical situation. However, our present studies stress the need for more information about other effects, since combined thyroid hormone and glucocorticoid therapy has recently been proposed in the amelioration of respiratory distress syndrome in the impending delivery of a premature infant (2 1).
Because newborn infants are deficient in the enzyme@) responsible for this conjugation reaction they frequently develop hyperbilirubinemia which is most often treated with phototherapy. During phototherapy, bilirubin undergoes two principal photochemical reactions, which yield products that are more polar than the native molecule (7-10). The relative importance of these two reactions to the therapeutic response seen with phototherapy depends on both the rates of formation and the rates of excretion of the photoproducts.
The two principal photoproducts are 42,l SE-bilirubin, a configurational isomer of the native 4Z, 15Z-bilirubin (9), and lumirubin, a structural isomer which contains a seven-member ring (10) (Fig. I) . The relative rates of the two reactions are known from in vitro studies (9-1 1) and appear to be similar in vivo (12) . The faster reaction is the configurational isomerization which is freely reversible. The formation of lumirubin occurs more slowly (1 1) but is essentially irreversible. Typically during phototherapy, 2 to 6% of the total bilirubin is present as lumirubin whereas 15 to 20% is present as the configurational isomer (12) . A third type of reaction, the photooxidation of bilirubin to mono and dipyrroles (1 3) occurs at a much lower rate than either isomerization reaction (1 1) and is not thought to be a quantitatively important pathway for bilirubin elimination.
The decline in serum bilirubin during phototherapy requires not only formation of these bilirubin isomers but also their elimination. The principal route of photoproduct elimination is thought to be through the bile. Onishi et al. (8) have reported finding a bilirubin photoproduct, which they called "unknown pigment," in the bile and urine of infants treated with phototherapy. We have used a high pressure liquid chromatographic method to quantitate the urinary excretion of bilirubin isomers in nine preterm infants. We have identified the photoproduct in the urine as the configurational isomer of bilirubin, lumirubin. We have determined the rate of urinary excretion of lumirubin
